Effect of St John's wort (Hypericum perforatum) on cytochrome P-450 activity in perfused rat liver

Life Sciences

Volumn 78, Issue 3, 2005, Pages 239-244

  Dostalek, M ^a   Pistovcakova, J ^a   Jurica, J ^a   Tomandl, J ^a   Linhart, I ^b   Sulcova A ^a   Hadasova, E ^a  

^a MASARYK UNIVERSITY   (Czech Republic)

^b INSTITUTE OF CHEMICAL TECHNOLOGY   (Czech Republic)

Author keywords

Cytochrome P 450; Drug interactions; St. John's wort

Indexed keywords

ANTIDEPRESSANT AGENT; CYTOCHROME P450; CYTOCHROME P450 2C; CYTOCHROME P450 2D; CYTOCHROME P450 3A2; DEXAMETHASONE; DEXTROMETHORPHAN; DEXTRORPHAN; DIAZEPAM; HYPERICUM PERFORATUM EXTRACT; KETOCONAZOLE; MIDAZOLAM; PHENOBARBITAL; QUININE; TOLBUTAMIDE;

ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CHEMICAL REACTION; CONTROLLED STUDY; DIET SUPPLEMENTATION; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPERICUM PERFORATUM; ISOLATED LIVER; LIVER PERFUSION; METABOLISM; NONHUMAN; RAT; VALIDATION PROCESS;

ANIMALS; ANTIDEPRESSIVE AGENTS; AREA UNDER CURVE; CYTOCHROME P-450 ENZYME SYSTEM; DEXTROMETHORPHAN; HERB-DRUG INTERACTIONS; HYPERICUM; INJECTIONS, INTRAPERITONEAL; LIVER; MALE; MIDAZOLAM; PERFUSION; PLANT EXTRACTS; RATS; RATS, WISTAR; TOLBUTAMIDE;

ANIMALIA; CINCHONA PUBESCENS; HYPERICUM PERFORATUM;

EID: 27644582764     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2005.04.055     Document Type: Article

References (40)

1. G.W. Baronet, B.J. Gurley, B.L. Kettel, M.L. Lightfood, and S.R. Abul-Ezz Drug interaction between St. John's wort and cyclosporine Annals of Pharmacotherapy 34 9 2000 1013 1016
2. S. Bauer, E. Stormer, R. Kerb, A. Johne, J. Brockmoller, and I. Roots Differential effects of Saint John's wort (Hypericum perforatum) on the urinary excretion of d-glucaric acid and 6-beta-hydroxycortisol in healthy volunteers European Journal of Clinical Pharmacology 58 2002 581 585
3. A.R. Bilia, S. Gallori, and F.F. Vincieri St. John's wort and depression. Efficacy safety and tolerability-an update Life Sciences 70 26 2002 1 20
4. T. Breindenbach, M.W. Hoffmann, T. Becker, H. Schlitt, and J. Klempnauer Drug interaction of St. John's wort with cyclosporine Lancet 355 9218 2000 1912
5. R. Brenner, V. Azbel, S. Madhusoodanan, and M. Pawlowska Comparison of an extract of Hypericum (LI 160) and sertraline in the treatment of depression: a double-blind, randomized pilot study Clinical Therapeutics 22 4 2000 411 419
6. S.S. Chatterjee, S.K. Bhattacharya, M. Wonnemann, A. Singer, and W.E. Muller Hyperforin as a possible antidepressant component of Hypericum extracts Life Sciences 63 6 1998 499 510
7. M.M. Cotreau, L.L. Von Moltke, M.C. Beinfeld, and D.J. Greenblatt Methodologies to study the induction of rat hepatic and intestinal and intestinal cytochrome P450 3A at the mRNA, protein and catalytic activity level Journal of Pharmacological and Toxicological Methods 43 1 2000 41 54
8. M.M.R. de Maat, R.M.W. Hoetelmans, R.A.A. Mathot, E.C.M. van Gorp, P.L. Meenhorst, J.W. Mulder, and J.H. Beijnen Drug interaction between St. John's wort and nevirapine AIDS 15 3 2001 420 421
9. E. Ernst, J.I. Rand, J. Barnes, and C. Stevinson Adverse effects profile of the herbal antidepressant St. John's wort (Hypericum perforatum L.) European Journal of Clinical Pharmacology 54 8 1998 589 594
10. A. Ghosal, H. Satoh, P.E. Thomas, E. Bush, and D. Moore Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cDNA-expressed human cytochrome P450 Drug Metabolism and Disposition 24 9 1996 940 947
11. G. Harrer, U. Schmidt, U. Kuhn, and A. Biller Comparison of equivalent between the St. John's wort extract LoHyp-57 and fluoxetine Arzneimittel- Forschung 49 4 1999 289 296
12. E. Henney Risk of drug interactions with St. John's wort The Journal of the American Medical Association 283 1 2000 1679
13. J.W. Ho, and D.E. Moody Determination of tolbutamide hydroxylation in rat liver microsomes by high-performance liquid chromatography: effect of psychoactive drugs on in vitro activity Life Sciences 52 1 1992 21 28
14. A.A. Izzo, and E. Ernst Interactions between herbal medicines and prescribed drugs: a systematic review Drug 61 15 2001 2163 2175
15. A. Johne, J. Brockmoller, S. Bauer, A. Maurer, M. Langheinrich, and I. Roots Pharmacokinetic interaction of digoxin with an herbal extract from St. John's wort (Hypericum perforatum) Clinical Pharmacology and Therapeutics 66 4 1999 338 345
16. A. Johne, J. Schmider, J. Brockmoller, A.M. Stadelmann, E. Stormar, S. Bauer, S. Scholler, M. Langheinrich, and I. Roots Decreased plasma levels of amitriptyline and its metabolites on co-medication with an extract from St. John's wort (Hypericum perforatum) Journal of Clinical Psychopharmacology 22 1 2002 46 54
17. S.T. Kaehler, C. Sinner, S.S. Chatterjee, and A. Philippu Hyperforin enhances the extra cellular concentrations of catecholamine, serotonin and glutamate in the rat locus coeruleus Neuroscience Letters 262 3 1999 199 202
18. M. Karliova, U. Treichel, M. Malago, A. Frilling, G. Genker, and C.E. Broelsch Interaction of Hypericum perforatum (St. John's wort) with cyclosporine A metabolism in a patient after liver transplantation Journal of Hepatology 33 5 2000 853 855
19. R.B. Kim, M.F. Fromm, C.H. Wandel, B. Leake, A.J.J. Wood, D.M. Roden, and G.R. Wilkinson The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors Journal of Clinical Investigation 101 2 1998 289 294
20. R.B. Kim, C. Wandel, B. Leake, M. Cvetkovic, M.F. Fromm, P.J. Dempsey, M.M. Roden, F. Belas, A.K. Chaudhary, D.M. Roden, A.J. Wood, and G.R. Wilkinson Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein Pharmaceutical Research 16 3 1999 408 414
21. K. Kobayashi, K. Urashima, N. Shimada, and K. Chiba Substrate specifity for rat cytochrome P450 (CYP) isoforms: screening with cDNA-expressed system of the rat Biochemical Pharmacology 63 5 2002 889 896
22. J.S. Markowitz, C.L. de Vane, D.W. Boulton, S.W. Carlson, Z. Nahas, and S.C. Risch Effect of St. John's wort (Hypericum perforatum) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers Life Sciences 66 9 2000 133 139
23. L.L. Miller, C.G. By, M.L. Watson, and W.F. Bale The dominant role of the liver in plasma protein synthesis Journal of Experimental Medicine 94 1951 431 453
24. A. Nahrstedt, and V. Butterweck Biological active and other chemical constituents of the herb of Hypericum perforatum L. Pharmacopsychiatry 30 Suppl. 2 1997 129 134
25. A. Nebel, B.J. Schneider, R.K. Baker, and D.J. Kroll Potential metabolic interaction between St. John's wort and theophylline Annals of Pharmacotherapy 33 4 1999 502
26. V. Nedelcheva, and I. Gut P450 in the rat and man: methods of investigation, substrate specificities and relevance to cancer Xenobiotika 24 12 1994 1151 1175
27. D.R. Nelson, L. Koymans, T. Kamataki, J.J. Stegeman, R. Feyereisen, D.J. Waxman, M.R. Waterman, O. Gotoh, M.J. Coon, R.W. Estabrook, I.C. Gunsalus, and D.W. Nebert P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature Pharmacogenetics 6 1 1996 1 42
28. M. Noldner, and S. Chattrerjee Effects of two different extracts of St. John's wort and some of their constituents on cytochrome P450 activities in the rat liver microsomes Pharmacopsychiatry 34 Suppl. 1 2001 108 110
29. R.S. Obach Inhibition of human cytochrome P450 enzymes by constituents of St John's wort, an herbal preparation used in the treatment of depression Journal of Pharmacology and Experimental Therapeutics 294 1 2000 88 95
30. S. Piscitelli, A.H. Burstein, D. Chaid, R. Alfaro, and J. Fallon Indinavir concentrations and St. John's wort Lancet 355 9203 2000 547 548
31. J.M. Rey, and G. Walter Hypericum perforatum (St. John's wort) in depression: pest or blessing? Medicinal Journal of Australia 169 11-12 1998 583 586
32. C.A. Roby, G.D. Anderson, E. Kantor, D.A. Dryer, and A.H. Burstein St. John's wort: effect on CYP3A4 activity Clinical Pharmacology and Therapeutics 67 5 2000 451 457
33. A.H. Schinkel, E. Wagenaar, C.A.A.M. Mol, and L. van Demmer P-glycoprotein in the barrier of mice influence the brain penetration and pharmacological activity of many drugs Journal of Clinical Investigation 97 11 1996 2517 2524
34. P. Soucek, and I. Gut Cytochromes P-450 in rats: structures, functions, properties and relevant human forms Xenobiotika 22 1 1992 83 103
35. K. Sugimoto, M. Ohmori, S. Tsuruoka, K. Nishiki, A. Kawaguchi, K. Harad, M. Arakawa, K. Sakamoto, M. Masada, I. Miyamori, and A. Fujimora Different effect of St. John's wort on the pharmacokinetics of simvastatin and pravastatin Clinical Pharmacology and Therapeutics 70 6 2001 518 524
36. E.U. Vorbach, K.H. Arnoldt, and W.D. Hubner Efficacy and tolerability of St. John's wort extract LI 160 versus imipramine in patients with severe depressive episodes according to ICD-10 Pharmacopsychiatry 30 Suppl. 2 1997 81 85
37. A. Walser, L.E. Benjamin, T. Flynn, C. Mason, R. Schwartz, and R.Y. Fryer Quinazolines and 1,4-benzodiazepines. 84. Synthesis and reactions of imidazol [1,5-α] [1,4] benzodiazepines Journal of Medicinal Chemistry 43 11 1978 936 944
38. Z. Wang, J.C. Gorski, M.A. Hamman, S.M. Huang, L.J. Lesko, and S.D. Hall The effects of St. John's wort (Hypericum perforatum) on human cytochrome P450 activity Clinical Pharmacology and Therapeutics 70 4 2001 317 326
39. D. Wheatley LI 160, an extract of St. John's wort, versus amitriptyline in mildly to moderately depressed outpatients-a controlled 6-week clinical trial Pharmacopsychiatry 30 Suppl. 2 1997 77 80
40. H. Woelk Comparison of St. John's wort and imipramine for treating depression: randomized controlled trial BMJ-Clinical Research 321 7260 2000 536 539